Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion
Background A systematic review of the outcomes of combination therapy using Yttrium 90 radioembolization (Y90) and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion. The aim of this study is to summarise the results of d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Proceedings of Singapore Healthcare |
| Online Access: | https://doi.org/10.1177/20101058231154666 |
| _version_ | 1797938349701332992 |
|---|---|
| author | Shiqi Chung Apoorva Gogna Sivanathan Chandramohan Richard Lo Farah Gillan Irani Nanda Venkatanarasimha |
| author_facet | Shiqi Chung Apoorva Gogna Sivanathan Chandramohan Richard Lo Farah Gillan Irani Nanda Venkatanarasimha |
| author_sort | Shiqi Chung |
| collection | DOAJ |
| description | Background A systematic review of the outcomes of combination therapy using Yttrium 90 radioembolization (Y90) and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion. The aim of this study is to summarise the results of different studies that used the combination therapy for HCC patients with tumor thrombosis involving the HV or IVC. Method A literature search was performed using keywords in Medline and Google Scholar limited to publications from 2010 to 2021. There were 173 articles identified during the initial literature search. During abstract screening, 81 articles were excluded. Another 83 did not contain information on hepatic vein or IVC invasion. Therefore, 9 articles met the eligibility criteria and were included in the synthesis. Results In total, 37 patients with hepatic vein or IVC invasion were identified. There were 31 patients who were given sorafenib, 7 were given nivolumab and 1 was given both sorafenib and nivolumab. Among the 37 patients, 21 had hepatic vein invasion, 22 had IVC invasion and 6 had both HV and IVC invasion. The median OS was 20.55 months and median PFS was 8.18 months. For the results, 23 patients were evaluated via modified RECIST (mRECIST) criteria and 14 were evaluated via RECIST 1.1. Conclusion The combination of local and systemic therapies demonstrated potential results for increased response rates, OS and PFS benefits. Further studies are required to determine the long-term outcomes of the combination therapy for this group of patients. |
| first_indexed | 2024-04-10T18:58:20Z |
| format | Article |
| id | doaj.art-cdab07494a12429b91c40aaa11f7a406 |
| institution | Directory Open Access Journal |
| issn | 2059-2329 |
| language | English |
| last_indexed | 2024-04-10T18:58:20Z |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Proceedings of Singapore Healthcare |
| spelling | doaj.art-cdab07494a12429b91c40aaa11f7a4062023-01-31T14:34:44ZengSAGE PublishingProceedings of Singapore Healthcare2059-23292023-01-013210.1177/20101058231154666Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasionShiqi ChungApoorva GognaSivanathan ChandramohanRichard LoFarah Gillan IraniNanda VenkatanarasimhaBackground A systematic review of the outcomes of combination therapy using Yttrium 90 radioembolization (Y90) and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion. The aim of this study is to summarise the results of different studies that used the combination therapy for HCC patients with tumor thrombosis involving the HV or IVC. Method A literature search was performed using keywords in Medline and Google Scholar limited to publications from 2010 to 2021. There were 173 articles identified during the initial literature search. During abstract screening, 81 articles were excluded. Another 83 did not contain information on hepatic vein or IVC invasion. Therefore, 9 articles met the eligibility criteria and were included in the synthesis. Results In total, 37 patients with hepatic vein or IVC invasion were identified. There were 31 patients who were given sorafenib, 7 were given nivolumab and 1 was given both sorafenib and nivolumab. Among the 37 patients, 21 had hepatic vein invasion, 22 had IVC invasion and 6 had both HV and IVC invasion. The median OS was 20.55 months and median PFS was 8.18 months. For the results, 23 patients were evaluated via modified RECIST (mRECIST) criteria and 14 were evaluated via RECIST 1.1. Conclusion The combination of local and systemic therapies demonstrated potential results for increased response rates, OS and PFS benefits. Further studies are required to determine the long-term outcomes of the combination therapy for this group of patients.https://doi.org/10.1177/20101058231154666 |
| spellingShingle | Shiqi Chung Apoorva Gogna Sivanathan Chandramohan Richard Lo Farah Gillan Irani Nanda Venkatanarasimha Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion Proceedings of Singapore Healthcare |
| title | Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion |
| title_full | Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion |
| title_fullStr | Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion |
| title_full_unstemmed | Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion |
| title_short | Review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib/nivolumab for HCC with hepatic vein or IVC invasion |
| title_sort | review of outcomes of combination therapy using yttrium 90 radioembolization and sorafenib nivolumab for hcc with hepatic vein or ivc invasion |
| url | https://doi.org/10.1177/20101058231154666 |
| work_keys_str_mv | AT shiqichung reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion AT apoorvagogna reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion AT sivanathanchandramohan reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion AT richardlo reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion AT farahgillanirani reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion AT nandavenkatanarasimha reviewofoutcomesofcombinationtherapyusingyttrium90radioembolizationandsorafenibnivolumabforhccwithhepaticveinorivcinvasion |